125 related articles for article (PubMed ID: 30322323)
1. Funding Hepatitis C Treatment in Correctional Facilities by Using a Nominal Pricing Mechanism.
Spaulding AC; Chhatwal J; Adee MG; Lawrence RT; Beckwith CG; von Oehsen W
J Correct Health Care; 2019 Jan; 25(1):15-24. PubMed ID: 30322323
[TBL] [Abstract][Full Text] [Related]
2. Five Questions Concerning Managing Hepatitis C in the Justice System: Finding Practical Solutions for Hepatitis C Virus Elimination.
Spaulding AC; Adee MG; Lawrence RT; Chhatwal J; von Oehsen W
Infect Dis Clin North Am; 2018 Jun; 32(2):323-345. PubMed ID: 29778259
[TBL] [Abstract][Full Text] [Related]
3. New Hepatitis C Drugs Are Very Costly And Unavailable To Many State Prisoners.
Beckman AL; Bilinski A; Boyko R; Camp GM; Wall AT; Lim JK; Wang EA; Bruce RD; Gonsalves GS
Health Aff (Millwood); 2016 Oct; 35(10):1893-1901. PubMed ID: 27702964
[TBL] [Abstract][Full Text] [Related]
4. Enforcement of Legal Remedies to Secure Hepatitis C Virus Treatment With Direct-Acting Antiviral Therapies in Correctional Facilities and Medicaid Programs.
Greenwald R; Waters P; Cayer S
Public Health Rep; 2020; 135(1_suppl):44S-49S. PubMed ID: 32735189
[No Abstract] [Full Text] [Related]
5. A Budget Impact Analysis of Newly Available Hepatitis C Therapeutics and the Financial Burden on a State Correctional System.
Nguyen JT; Rich JD; Brockmann BW; Vohr F; Spaulding A; Montague BT
J Urban Health; 2015 Aug; 92(4):635-49. PubMed ID: 25828149
[TBL] [Abstract][Full Text] [Related]
6. Access to medicines and hepatitis C in Africa: can tiered pricing and voluntary licencing assure universal access, health equity and fairness?
Assefa Y; Hill PS; Ulikpan A; Williams OD
Global Health; 2017 Sep; 13(1):73. PubMed ID: 28903757
[TBL] [Abstract][Full Text] [Related]
7. Estimated Changes in Manufacturer and Health Care Organization Revenue Following List Price Reductions for Hepatitis C Treatments.
Dickson S; Reynolds I
JAMA Netw Open; 2019 Jul; 2(7):e196541. PubMed ID: 31276176
[TBL] [Abstract][Full Text] [Related]
8. Universal opt-out screening for hepatitis C virus (HCV) within correctional facilities is an effective intervention to improve public health.
Morris MD; Brown B; Allen SA
Int J Prison Health; 2017 Sep; 13(3-4):192-199. PubMed ID: 28914118
[TBL] [Abstract][Full Text] [Related]
9. Role Of Generics In Treatment Of Hepatitis C Infection.
Umar M; Akhter TS; Akbar I; Nisar G; Osama M; Akhter TS
J Ayub Med Coll Abbottabad; 2016; 28(4 Suppl 1):S890-S894. PubMed ID: 28782339
[TBL] [Abstract][Full Text] [Related]
10. Prices, Costs, and Affordability of New Medicines for Hepatitis C in 30 Countries: An Economic Analysis.
Iyengar S; Tay-Teo K; Vogler S; Beyer P; Wiktor S; de Joncheere K; Hill S
PLoS Med; 2016 May; 13(5):e1002032. PubMed ID: 27243629
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of cost-effectiveness of peginterferon plus ribavirin for chronic hepatitis C treatment and direct-acting antiviral agents among HIV-infected patients in the prison and community settings.
Chen CP; Cheng CY; Zou H; Cheng CH; Cheng SH; Chen CK; Chen CH; Bair MJ
J Microbiol Immunol Infect; 2019 Aug; 52(4):556-562. PubMed ID: 30360951
[TBL] [Abstract][Full Text] [Related]
12. New opportunities for the management and therapy of hepatitis C in correctional settings.
Martin CK; Hostetter JE; Hagan JJ
Am J Public Health; 2010 Jan; 100(1):13-7. PubMed ID: 20007626
[TBL] [Abstract][Full Text] [Related]
13. An innovative approach to pharmacy management in a state correctional system.
Marcoux RM; Simeone JC; Colavita M; Larrat EP
J Correct Health Care; 2012 Jan; 18(1):53-61. PubMed ID: 22013144
[TBL] [Abstract][Full Text] [Related]
14. Economic evaluation of the hepatitis C elimination strategy in Greece in the era of affordable direct-acting antivirals.
Gountas I; Sypsa V; Papatheodoridis G; Souliotis K; Athanasakis K; Razavi H; Hatzakis A
World J Gastroenterol; 2019 Mar; 25(11):1327-1340. PubMed ID: 30918426
[TBL] [Abstract][Full Text] [Related]
15. State Medicaid Reimbursement for Medications for Chronic Hepatitis C Infection from 2012 through 2015.
Lu CY; Zhang F; Golonski N; Lupton C; Jeffrey P; Wagner AK
Value Health; 2018 Jun; 21(6):692-697. PubMed ID: 29909874
[TBL] [Abstract][Full Text] [Related]
16. Telementoring for hepatitis C treatment in correctional facilities.
Neuhaus M; Langbecker D; Caffery LJ; Taylor M; Garner L; Williams G; Smith AC; Macdonald GA
J Telemed Telecare; 2018 Dec; 24(10):690-696. PubMed ID: 30343659
[TBL] [Abstract][Full Text] [Related]
17. Pathways to ensure universal and affordable access to hepatitis C treatment.
Douglass CH; Pedrana A; Lazarus JV; 't Hoen EFM; Hammad R; Leite RB; Hill A; Hellard M
BMC Med; 2018 Oct; 16(1):175. PubMed ID: 30296935
[TBL] [Abstract][Full Text] [Related]
18. Hepatitis C in state correctional facilities.
Spaulding A; Greene C; Davidson K; Schneidermann M; Rich J
Prev Med; 1999 Jan; 28(1):92-100. PubMed ID: 9973592
[TBL] [Abstract][Full Text] [Related]
19. Uptake of and Expenditure on Direct-Acting Antiviral Agents for Hepatitis C Treatment in Australia.
de Graaff B; Yee KC; Clarke P; Palmer A
Appl Health Econ Health Policy; 2018 Aug; 16(4):495-502. PubMed ID: 29675692
[TBL] [Abstract][Full Text] [Related]
20. Exploring the Case for Eminent Domain of Hepatitis C Virus Treatment Patents.
Mattingly Ii TJ; Heil EL; Hoke KS
J Health Care Poor Underserved; 2017; 28(2):621-625. PubMed ID: 28529212
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
